Clinical trials: Hematologic and Lymphocytic Disorder
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine with or without ventoclax in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03634228
- Testing
- Cytarabine, Milademetan Tosylate, Venetoclax
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
This phase I/II studies the side effects and best dose of natural killer cells before and after donor stem cell transplant and to see how well they work in treating patients with acute myeloid leukemia, myelodysplastic syndrome…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01904136
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
This is a single-center randomized phase 2 open-label clinical trial.
- Conditions
- Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
- Trial name
- NCT07710534
- Testing
- Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Hemophilia A
Joint Health, Balance and Quality of Life in Adults With Hemophilia A
Hemophilia is a hereditary bleeding disorder characterized by recurrent bleeding episodes, particularly into joints and muscles, leading to chronic musculoskeletal complications.
- Trial name
- NCT07523399
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Yuzuncu Yil University
Immune Thrombocytopenia (ITP)
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.
- Trial name
- NCT07416032
- Testing
- QT-019C
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Immune Thrombocytopenia (ITP)
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
This study is a nationwide, multicenter, retrospective, real-world, non-interventional (observational) investigation. It retrospectively collects data on treatment modalities and therapeutic responses in patients with newly…
- Trial name
- NCT07268898
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00528398
- Testing
- cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- City of Hope Medical Center
Cytopenia, MDS
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells…
- Trial name
- NCT07081087
- Testing
- PERIBLOOD-MDS
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Weizmann Institute of Science
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.
- Trial name
- NCT06134414
- Testing
- MY008211A tablets
- Volunteers
- 40 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Prostate Cancer, Leukemia
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Study Description: ELEA is an observational cohort study that will collect exposure information and biospecimens from the adult children of the Agricultural Health Study (AHS) cohort (https://aghealth.nih.gov/about; Protocol…
- Conditions
- Prostate Cancer, Leukemia, Breast Cancer, Melanoma
- Trial name
- NCT07328516
- Where
- United States
- Volunteers
- 64,277 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
- Trial name
- NCT07220616
- Testing
- DS3790a, Combination drug
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 420 people
- Sponsor
- Daiichi Sankyo
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin
The purpose of this study is to determine the safety and feasibility of conditioning with fludarabine, busulphan and thymoglobuline in patients with myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative disorders…
- Trial name
- FB-ATG (NCT00915811)
- Testing
- Fludarabine, Busulphan, Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Leukemia, B-cell
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B…
- Trial name
- NCT06209671
- Testing
- INS19 CAR-T Cells
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Leukemia
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00100971
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, tumor cell-derivative vaccine therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Boston Medical Center
COVID, Disseminated Intravascular Coagulation
Coagulation Changes Associated With COVID-19 Infection
This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
- Conditions
- COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
- Trial name
- NCT04460664
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HemoSonics LLC
Acute Promyelocytic Leukemia
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
- Trial name
- Ven APL (NCT06544109)
- Testing
- venetoclax
- Where
- China
- Volunteers
- 98 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Background: Ofatumumab was approved by the U.S. Food and Drug Administration to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not responded to standard chemotherapy.
- Trial name
- NCT01145209
- Testing
- Fludarabine Phosphate, Ofatumumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I trial studies the side effects and determine the best dose of prexasertib (LY2606368) when given together with cytarabine and fludarabine in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome…
- Conditions
- Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02649764
- Testing
- Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation with TCR alpha/beta grafts depletion in patient with…
- Conditions
- Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation, Graft Failure
- Trial name
- NCT03019809
- Testing
- G-CSF for Conditioning before HSCT., Plerixafor for Conditioning before HSCT.
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Myelofibrosis, Post-PV MF
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
- Conditions
- Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
- Trial name
- NCT04640532
- Testing
- KRT-232, TL-895
- Where
- 37 sites in United States, Austria and 8 more
- Volunteers
- 116 people
- Sponsor
- Kartos Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.